Kronos Bio, Inc. (NASDAQ:KRON – Get Free Report) shares shot up 1.1% during trading on Wednesday . The company traded as high as $1.00 and last traded at $0.96. 883,997 shares traded hands during trading, an increase of 192% from the average session volume of 302,912 shares. The stock had previously closed at $0.95.
Kronos Bio Trading Up 1.1 %
The business has a fifty day simple moving average of $1.15 and a 200 day simple moving average of $1.12. The stock has a market capitalization of $57.70 million, a P/E ratio of -0.49 and a beta of 1.82.
Kronos Bio (NASDAQ:KRON – Get Free Report) last announced its quarterly earnings data on Thursday, March 21st. The company reported ($0.43) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.08. Kronos Bio had a negative return on equity of 58.79% and a negative net margin of 1,791.87%. The firm had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $1.50 million. As a group, research analysts forecast that Kronos Bio, Inc. will post -1.74 earnings per share for the current year.
Institutional Trading of Kronos Bio
Kronos Bio Company Profile
Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. The company's lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.
Featured Articles
- Five stocks we like better than Kronos Bio
- Basic Materials Stocks Investing
- High-Yield Texas Instruments Could Hit New Highs Soon
- The 3 Best Blue-Chip Stocks to Buy Now
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Kronos Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kronos Bio and related companies with MarketBeat.com's FREE daily email newsletter.